Vela Investment Management, LLC Vertex Pharmaceuticals Inc Transaction History

Vela Investment Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 30, 2024	SELL	$343.0 - $410.68 $215,404 - $257,907	-628 Reduced 6.87%	8,507 $3.46 Million
Q3 2023 Nov 07, 2023	BUY	$338.18 - $362.46 $94,014 - $100,763	278 Added 3.14%	9,135 $3.18 Million
Q2 2023 Aug 08, 2023	SELL	$314.42 - $351.91 $259,710 - $290,677	-826 Reduced 8.53%	8,857 $3.12 Million
Q1 2023 May 08, 2023	BUY	$283.23 - $323.1 $239,612 - $273,342	846 Added 9.57%	9,683 $3.05 Million
Q4 2022 Jan 31, 2023	BUY	$285.76 - $321.48 $9,715 - $10,930	34 Added 0.39%	8,837 $2.55 Million
Q3 2022 Nov 10, 2022	SELL	$273.83 - $305.53 $129,247 - $144,210	-472 Reduced 5.09%	8,803 $2.55 Million
Q2 2022 Aug 11, 2022	BUY	$234.96 - $292.55 $212,638 - $264,757	905 Added 10.81%	9,275 $2.61 Million
Q1 2022 May 12, 2022	BUY	$221.42 - $260.97 $174,921 - $206,166	790 Added 10.42%	8,370 $2.18 Million
Q4 2021 Feb 09, 2022	BUY	$177.01 - $223.45 $1.34 Million - $1.69 Million	7,580 New	7,580 $1.67 Million

1,707

226M

1.2M

1.59M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Vela Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Vela Investment Management, LLC with notifications on news.